- Conditions
- HCV Infection
- Interventions
- GS-9450, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 48 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
- Interventions
- enzastaurin, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Idelalisib, Rituximab, Placebo to match idelalisib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 27 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Idelalisib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 24 more
- Conditions
- Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
- Interventions
- lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HCV Infection
- Interventions
- placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 48
- States / cities
- Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
- Conditions
- Predictive Validity of VLaHHS
- Interventions
- Training with Virtual Laparoscopic Hiatal Hernia Simulator (VLaHHS)
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
- Conditions
- Severe Alcoholic Hepatitis
- Interventions
- GS-4997, Prednisolone, HepQuant SHUNT Test, Placebo
- Drug · Device
- Lead sponsor
- HepQuant, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 13
- States / cities
- Coronado, California • Miami, Florida • Atlanta, Georgia + 9 more